The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sugurova A.T.

Bashkir State Medical University

Yashchuk A.G.

Bashkir State Medical University

Khusainov R.I.

Bashkir State Medical University

Clinical and genetic aspects of the problem of ovarian response when using assisted reproductive technologies

Authors:

Sugurova A.T., Yashchuk A.G., Khusainov R.I.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6): 48‑55

DOI: 10.17116/rosakush20202006148

Views: 1770

Downloaded: 68

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Sugurova AT, Yashchuk AG, Khusainov RI. Clinical and genetic aspects of the problem of ovarian response when using assisted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6):48‑55. (In Russ.)
https://doi.org/10.17116/rosakush20202006148

 
МСФ на ЯМ
Close metadata
Recommended articles:
Arti­ficial inte­lligent systems in the deve­lopment of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):19-29
Correlation depe­ndence of tissue inhi­bitor of meta­lloproteinase-1 levels and follicular fluid morphology in patients with combined (uterine myoma and endo­metriosis) infe­rtility in the ART-programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):21-28
Comparative analysis of oocyte quality in patients with tubal-peritoneal gene­sis of infe­rtility in assi­sted reproductive technology programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):41-49
The expe­rience of using the nasal form of GnRH agonists in in vitro fertilization programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):79-84
The role of inte­rgenic inte­ractions in the formation of peri­natal complications of gestational diabetes mellitus in pregnant women after assi­sted reproductive technologies. Russian Journal of Human Reproduction. 2024;(2):51-61
Assi­sted reproductive technologies and the risk of placenta accreta. Russian Journal of Human Reproduction. 2024;(3):43-49
Calcium-phosphorus meta­bolism and assi­sted reproductive technologies: inte­rsection points. Russian Journal of Human Reproduction. 2024;(4):19-28
The dile­mma of mana­gement of patients with endo­metrioma and infe­rtility. Russian Journal of Human Reproduction. 2024;(4):29-37
The place of GnRH anta­gonists in modern ART programs: the possibilities of using of new drug of gani­relix. Russian Journal of Human Reproduction. 2024;(4):38-50
Regu­latory control of gestagens use in Russia in the era of indi­vidualized luteal phase support for assi­sted reproduction cycles. Russian Journal of Human Reproduction. 2024;(4):59-70

The systematization of published scientific works on the problem of ovarian response under controlled stimulation of superovulation in programs of assisted reproductive technologies has been carried out. New possibilities in predicting the ovarian response using genetic markers are described. In the future, pharmaceutical-genetic / genomic research will lead to an epoch when the human DNA structure will be taken as integral part for rationale drug therapy. The prognosis of ovarian response to controlled ovarian stimulation will include a combination of phenotypic and genetic markers that will be used in routine diagnostic tests prior to superovulation stimulation in assisted reproductive technology programs. The patient’s genetic profile will be used to select the most appropriate gonadotropin type, optimal drug dosage and shorten the time to pregnancy setup.

Keywords:

genetic predictors of ovarian response
assisted reproductive technologies
weak ovarian response

Authors:

Sugurova A.T.

Bashkir State Medical University

Yashchuk A.G.

Bashkir State Medical University

Khusainov R.I.

Bashkir State Medical University

Received:

18.02.2020

Accepted:

01.04.2020

List of references:

  1. Pastore LM, Christianson MS, Stelling J, Kearns WG, Segars JH. Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POR, and FOR. J Assist Reprod Genet. 2018;35:1:17-23.  https://doi.org/10.1007/s10815-017-1058-4
  2. Vaiarelli A, Cimadomo D, Ubaldi N, Rienzi L, Ubaldi FM. What is new in the management of poor ovarian response in IVF? Curr Opin Obstet Gynecol. 2018;30:3:155-162.  https://doi.org/10.1097/GCO.0000000000000452
  3. Haahr T, Esteves SC, Humaidan P Individualized controlled ovarian stimulation in expected poor-responders: an update. Reprod Biol Endocrinol. 2018;16:1:20.  https://doi.org/10.1186/s12958-018-0342-1
  4. Sighinolfi G, Grisendi V, La Marca A. How to personalize ovarian stimulation in clinical practice. J Turk Ger Gynecol Assoc. 2017;18:3:148-153.  https://doi.org/10.4274/jtgga.2017.0058.
  5. Gonda KJ, Domar AD, Gleicher N, Marrs RP. Insights from clinical experience in treating IVF poor responders. Reprod Biomed Online. 2018;36:1:12-19.  https://doi.org/10.1016/j.rbmo.2017.09.016
  6. Zhang W, Wang M, Wang S, Bao H, Qu Q, Zhang N, Hao C Luteal phase ovarian stimulation for poor ovarian responders. JBRA Assist Reprod. 2018;22(3):193-198.  https://doi.org/10.5935/1518-0557.20180045
  7. Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, Torrance H, Broekmans FJ. Individualised gonadotropin dose selection using markers of ovarian reserve y for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev. 2018;2:CD012693. https://doi.org/10.1002/14651858
  8. Sanverdi I, Ozkaya E, Kucur SK, Bilen D, Eken MK, Bilgic BE. Antral follicle diameter variance within each ovary may be a predictor for poor response in cases with normal ovarian reserve. Exp Clin Endocrinol Diabetes. 2018;126:8:521-527.  https://doi.org/10.1055/s-0043-125404
  9. Rasool S, Shah D. Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel’s back. Fertil Res Pract. 2017;3:15.  https://doi.org/10.1186/s40738-017-0041-1
  10. Joaquín Errázuriz, Alessia Romito, Panagiotis Drakopoulos, Billie Frederix, Analissa Racca, Neelke De Munck, Herman Tournaye, Michel De Vos, and Christophe Blockeel. Cumulative live birth rates following stimulation with corifollitropin alfa compared with hp-hMG in a GnRH antagonist protocol in poor ovarian responders front endocrinol (Lausanne). Publishedonline. 2019;10:75. PMCID: PMC6439614PMID: 30967840. https://doi.org/10.3389/fendo.2019.00175
  11. Yadava Bapurao Jeve and Harish Malappa Bhandari. Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. J Hum Reprod Sci. 2016;9:2:70-81.  https://doi.org/10.4103/0974-1208.183515
  12. Szmidt NA, Bhattacharya S, Maheshwari A. Does poor ovarian response to gonadotrophins predict early menopause? A retrospective cohort study with minimum of 10-year follow-up. Hum Fertil (Camb). 2016;19:3:212-219.  https://doi.org/10.1080/14647273.2016.1221149
  13. Xu B, Chen Y, Geerts D, Yue J, Li Z, Zhu G, Jin L. Cumulative live birth rates in more than 3,000 patients with poor ovarian response: a 15-year survey of final in vitro fertilization outcome. Fertil Steril. 2018;109:6:1051-1059. https://doi.org/10.1016/j.fertnstert.2018.02.001
  14. Yin H, Jiang H, He R, Wang C, Zhu J, Cao Z. Cumulative live birth rate of advanced-age women more than 40 with or without poor ovarian response. Taiwan J Obstet Gynecol. 2019;58:2:201-205.  https://doi.org/10.1016/j.tjog.2019.01.006
  15. Yakovi S, Izhaki I, Ben-Ami M, Younis JS. Does the empty follicle syndrome occur in cases of low number of maturing follicles in assisted reproduction? Gynecol Endocrinol. 2019;35:4:305-308.  https://doi.org/10.1080/09513590.2018.1519793
  16. Su YT, Lin PY, Huang FJ, Kung FT, Lin YJ, Tsai YR, Lan KC, Age is a major prognosticator in extremely low oocyte retrieval cycles. Taiwan J Obstet Gynecol. 2017;56:2:175-180.  https://doi.org/10.1016/j.tjog.2016.04.039
  17. Meczekalski B, Czyzyk A, Kunicki M, Podfigurna-Stopa A, Plociennik L, Jakiel G, Maciejewska-Jeske M, Lukaszuk K. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. J Endocrinol Invest. 2016;39:11:1259-1265. Review. Erratum in: J Endocrinol Invest. 2016;39:11:1267.
  18. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Comparing four ovarian reserve markers-associations with ovarian response and live births after assisted reproduction. Acta Obstet Gynecol Scand. 2015;94:10:1056-1063. https://doi.org/10.1111/aogs.12710
  19. Baker VL, Gracia C, Glassner MJ, Schnell VL, Doody K, Coddington CC, Shin SS, Marshall LA, Alper MM, Morales AJ, Pavone ME, Behera MA, Zbella EA, Shapiro BS, Straseski JA, Broyles DL. Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation. Fertil Steril. 2018;110:3:506-513.e3.  https://doi.org/10.1016/j.fertnstert.2018.03.031
  20. Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reprod Biomed Online. 2015;31:4:486-496.  https://doi.org/10.1016/j.rbmo.2015.06.015
  21. Zheng H, Chen S, Du H, Ling J, Wu Y, Liu H, Liu J. Ovarian response prediction in controlled ovarian stimulation for IVF using anti-Müllerian hormone in Chinese women: A retrospective cohort study. Medicine (Baltimore). 2017;96:13:e6495. https://doi.org/10.1097/MD.0000000000006495
  22. Izhar R, Husain S, Tahir S, Husain S. Occult form of premature ovarian insufficiency in women with infertility and oligomenorrhea as assessed by poor ovarian response criteria. J Reprod Infertil. 2017;18:4:361-367. 
  23. Amaral MEB, Ejzenberg D, Wajman DS, Monteleone PAA, Serafini P, Soares JM Jr, Baracat EC. Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review. J Assist Reprod Genet. 2019;36:1:19-28.  https://doi.org/10.1007/s10815-018-1324-0
  24. Sandro C Esteves, Matheus Roque, Giuliano M Bedoschi, Alessandro Conforti, Peter Humaidan and Carlo Alviggi. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON Criteria — The Why, Front Endocrinol (Lausanne). 2018;9:461. Published online 2018 Aug 17. PMCID: PMC6107695 PMID: 30174650. https://doi.org/10.3389/fendo.2018.00461
  25. Hojnik N, Vlaisavljević V, Kovačič B, Morphokinetic Characteristics and developmental potential of in vitro cultured embryos from natural cycles in patients with poor ovarian response. B Biomed Res Int. 2016;2016:4286528. https://doi.org/10.1155/2016/4286528
  26. Giovanna Sighinolfi, Valentina Grisendi, and Antonio La Marca. How to personalize ovarian stimulation in clinical practice. J Turk Ger Gynecol Assoc. 2017;18:3:148-153. Published online 2017 Sep 1. PMCID: PMC5590212 PMID: 28890430. https://doi.org/10.4274/jtgga.2017.0058
  27. Vural B, Cakiroglu Y, Vural, The predictor markers of ovarian response in poor responders under 40 years of age. F Clin Exp Obstet Gynecol. 2016;43:5:650-653. 
  28. Zhang J. Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders? Reprod Biol Endocrinol. 2015;13:76.  https://doi.org/10.1186/s12958-015-0076-2
  29. Monteiro CS, Scheffer BB, Carvalho RF, Scheffer JB. The impact of dehydroepiandrosterone in poor ovarian responders on assisted reproduction technology treatment. JBRA Assist Reprod. 2019 Jun 28.  https://doi.org/10.5935/1518-0557.20190045
  30. Ata B, Seyhan A, Seli E. Diminished ovarian reserve versus ovarian aging: overlaps and differences. Curr Opin Obstet Gynecol. 2019;31:3:139-147.  https://doi.org/10.1097/GCO.0000000000000536
  31. Yang Y, Sun X, Cui L, Sheng Y, Tang R, Wei D, Qin Y, Li W, Chen Z. Younger poor ovarian response women achieved better pregnancy results in the first three IVF cycles. J Reprod Biomed Online. 2016;32:5:532-527.  https://doi.org/10.1016/j.rbmo.2016.02.013
  32. Grisendi V, Mastellari E, La Marca A. Ovarian reserve markers to identify poor responders in the context of poseidon classification. Front Endocrinol (Lausanne). 2019;10:281.  https://doi.org/10.3389/fendo.2019.00281
  33. Humaidan P, Schertz J, Fischer R. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment. BMJ Open. 2015;5:7:e008297. https://doi.org/10.1136/bmjopen-2015-008297
  34. Liu C, Jiang H, Zhang W, Yin H. Double ovarian stimulation during the follicular and luteal phase in women ≥38 years: a retrospective case-control study. Reprod Biomed Online. 2017;35:6:678-684.  https://doi.org/10.1016/j.rbmo.2017.08.019
  35. Vaiarelli A, Cimadomo D, Trabucco E, Vallefuoco R, Buffo L, Dusi L, Fiorini F, Barnocchi N, Bulletti FM, Rienzi L, Ubaldi FM. Double stimulation in the same ovarian cycle (DuoStim) to maximize the number of oocytes retrieved from poor prognosis patients: a multicenter experience and SWOT analysis. Front Endocrinol (Lausanne). 2018;9:317.  https://doi.org/10.3389/fendo.2018.00317
  36. Alsbjerg B, Haahr T, Elbaek HO, Laursen R, Povlsen BB, Humaidan P. Dual stimulation using corifollitropin alfa in 54 bologna criteria poor ovarian responders — a case series. Reprod Biomed Online. 2019;38:5:677-682.  https://doi.org/10.1016/j.rbmo.2019.01.007
  37. Selman H, Rinaldi L. Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. Int J Womens Health. 2016;8:609-615.  https://doi.org/10.2147/IJWH.S117577
  38. van Tilborg TC, Oudshoorn SC, Eijkemans MJC, Mochtar MH, van Golde RJT, Hoek A, Kuchenbecker WKH, Fleischer K, de Bruin JP, Groen H, van Wely M, Lambalk CB, Laven JSE, Mol BWJ, Broekmans FJM, Torrance HL. OPTIMIST study group, individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. Hum Reprod. 2017;32:12:24852495. https://doi.org/10.1093/humrep/dex321
  39. Norman RJ, Alvino H, Hull LM, Mol BW, Hart RJ, Kelly TL, Rombauts L. LIGHT investigators, human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online. 2019;38:6:908-915.  https://doi.org/10.1016/j.rbmo.2019.02.003
  40. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, van der Veen F, van Wely M. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:5:560-579.  https://doi.org/10.1093/humupd/dmx017
  41. Heijnen EM, Eijkemans MJ, De Klerk C, Polinder S, Beckers NG, Klinkert ER, Broekmans FJ, Passchier J, Te Velde ER, Macklon NS, Fauser BC. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet. 2007;369:9563:743-749. 
  42. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, Macklon NS, Fauser BC. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod. 2007;22:4:980-988. 
  43. Madani T, Hemat M, Arabipoor A, Khodabakhshi SH, Zolfaghari Z. Double mild stimulation and egg collection in the same cycle for management of poor ovarianresponders. J Gynecol Obstet Hum Reprod. 2019;48:5:329-333.  https://doi.org/10.1016/j.jogoh.2018.12.004
  44. Hassan AMA, Kotb MMM, AwadAllah AMA, Shehata NAA, Wahba A. Follicular sensitivity index (FSI): a novel tool to predict clinical pregnancy rate in IVF/ICSI cycles. J Assist Reprod Genet. 2017;34:10:1317-1324. https://doi.org/10.1007/s10815-017-0984-5
  45. Morin SJ, Kaser DJ, Franasiak JM. The dilemma of aneuploidy screening on low responders. Curr Opin Obstet Gynecol. 2018;30:3:179-184.  https://doi.org/10.1097/GCO.0000000000000449
  46. Wang T, Zhang M, Jiang Z, Seli E. Mitochondrial dysfunction and ovarian aging. Am J Reprod Immunol. 2017;77:5.  https://doi.org/10.1111/aji.12651
  47. Tianqi Wang, Zhengao Sun, June Ping Lim, and Yi Yu. Comparison of luteal phase ovulation induction and ultra-short gonadotropin-releasing hormone agonist protocols in older patients undergoing in vitro fertilization. Libyan J Med. 2019;14:1:1597327. https://doi.org/10.1080/19932820.2019.1597327
  48. Drakopoulos P, Romito A, Errázuriz J, Santos-Ribeiro S, Popovic-Todorovic B, Racca A, Tournaye H, De Vos M, Blockeel C, Modified natural cycle IVF versus conventional stimulation in advanced-age Bologna poorresponders. C Reprod Biomed Online. 2019; pii: S1472-6483(19)30547-4.  https://doi.org/10.1016/j.rbmo.2019.05.009
  49. Leijdekkers JA, Eijkemans MJC, van Tilborg TC, Oudshoorn SC, van Golde RJT, Hoek A, Lambalk CB, de Bruin JP, Fleischer K, Mochtar MH, Kuchenbecker WKH, Laven JSE, Mol BWJ, Torrance HL, Broekmans FJM; OPTIMIST stud,y group. Cumulative live birth rates in low-prognosis women. Hum Reprod. 2019;34:6:1030-1041. https://doi.org/10.1093/humrep/dez051
  50. Abrahami N, Izhaki I, Younis JS. Do young women with unexplained infertility show manifestations of decreased ovarian reserve? J Assist Reprod Genet. 2019;36:6:1143-1152. https://doi.org/10.1007/s10815-019-01467-0
  51. Duport Percier M, Anahory T, Ranisavljevic N, Bringer-Deutsch S. Poor responders: how could we improve our results? Gynecol Obstet Fertil Senol. 2017;45:2:95-103.  https://doi.org/10.1016/j.gofs.2016.12.023
  52. Youssef MA, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, Alhalabi M, Akhondi M, Ansaripour S, Tokhmechy R, Zarandi L, Rizk A, El-Mohamedy M, Shaeer E, Khattab M, Mochtar MH, van der Veen F. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Hum Reprod. 2017;32:1:112-118. 
  53. Maruška Čuš, Veljko Vlaisavljević, Katja Repnik, Uroš Potočnik, and Borut Kovačič. Could polymorphisms of some hormonal receptor genes, involved in folliculogenesis help in predicting patient response to controlled ovarian stimulation? J Assist Reprod Genet. 2019;36:1:47-55.  https://doi.org/10.1007/s10815-018-1357-4
  54. Valentina Grisendi, Elisa Mastellari, andAntonio La Marca. Ovarian reserve markers to identify poor responders in the context of poseidon classification. Front Endocrinol (Lausanne). 2019;10:281.  https://doi.org/10.3389/fendo.2019.00281
  55. Jing Zhuang, Hengli Li, Xiaohong Li, Dongmei Tian, Dan Yang, and Minghui Zhu. The incidence of unexpected poor ovarian response in Chinese young women. Medicine. 2019;98:7:e14379. https://doi.org/10.1097/MD.0000000000014379
  56. Roque M, Bianco B, Christofolini DM, Barchi Cordts E, Vilarino F, Carvalho W, Valle M, Sampaio M, Geber S, Esteves SC, Parente Barbosa C, Panminerva Med. 2019;61:1:76-81.  https://doi.org/10.23736/S0031-0808.18.03496-1
  57. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007;81:3:328-345.  https://doi.org/10.1038/sj.clpt.6100087
  58. Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17:6:813-828.  https://doi.org/10.1093/humupd/dmr034
  59. Lledo B, Ortiz JA, Llacer J, Bernabeu R. Pharmacogenetics of ovarian response. Pharmacogenomics. 2014;15:6:885-893.  https://doi.org/10.2217/pgs.14.49
  60. Francisco de Castro, Rocío Ruiz, Luis Montoro, Dámaso Pérez-Hernández, Elisa Sánchez-Casas Padilla, Luis M Real, Agustín Ruiz. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil Steril. 2003;80:3:571-576.  https://doi.org/10.1016/s0015-0282(03)00795-7
  61. Polyzos NP, Sunkara SK. Sub-optimal responders following controlled ovarian stimulation: an overlooked group? Hum Reprod. 2015;30:9:2005-2008. https://doi.org/10.1093/humrep/dev149
  62. Riccetti L, De Pascali F, Gilioli L, Santi D, Brigante G, Simoni M, Casarini L. Genetics of gonadotropins and their receptors as markers of ovarian reserve and response in controlled ovarian stimulation. Best Pract Res Clin Obstet Gynaecol. 2017;44:15-25.  https://doi.org/10.1016/j.bpobgyn.2017.04.002
  63. Maritza Perez Mayorga, Jörg Gromoll, Hermann M. Behre, Claudia Gassner, Eberhard Nieschlag, Manuela Simoni. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab. 2000;85:9:3365-3369. https://doi.org/10.1210/jcem.85.9.6789
  64. Noel Pabalan, Camila Martins Trevisan, Carla Peluso, Hamdi Jarjanazi, Denise Maria Christofolini, Caio Parente Barbosa, Bianca Bianco. Evaluating influence of the genotypes in the follicle-stimulating hormone receptor (FSHR) Ser680Asn (rs6166) polymorphism on poor and hyper-responders to ovarian stimulation: a meta-analysis. J Ovarian Res. 2014;7:285.  https://doi.org/10.1186/s13048-014-0122-2
  65. Huang X, Li L, Hong L, Zhou W, Shi H, Zhang H, Zhang Z, Sun X. The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation. J Clin Endocrinol (Oxf). 2015;82:4:577-583.  https://doi.org/10.1111/cen.12573
  66. Huilin Tang, Yingying Yan, Tiansheng Wang, Ting Zhang, Weilong Shi, Rong Fan, Yao Yao, Suodi Zhai. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. J Assist Reprod Genet. 2015;32:12:1801-1810. https://doi.org/10.1007/s10815-015-0600-5
  67. Zeng S, Wang X, Wang Y, Xu Z, Zhang J, Liu W, Qian L, Chen X, Wei J, Yang X, Gong Z, Yan Y. MTHFR C677T polymorphism is associated with follicle-stimulating hormone levels and controlled ovarian hyperstimulation response: a retrospective study from the clinical database. Fertil Steril. 2019;111:5:982-990.e2.  https://doi.org/10.1016/j.fertnstert.2019.01.016
  68. Yin Q, Li Y, Huang J, Yang D, Zhonghua Yi Xue Yi Chuan Xue Za Zhi. Association of rs13405728 polymorphism of LHR gene with slow ovarian response. 2015;32:6:840-843.  https://doi.org/10.3760/cma.j.issn.1003-9406.2015.06.020
  69. Motawi TMK, Rizk SM, Maurice NW, Maged AM, Raslan AN, Sawaf AH, The role of gene polymorphisms and AMH level in prediction of poor ovarian response in Egyptian women undergoing IVF procedure. J Assist Reprod Genet. 2017;34:12:1659-1666. https://doi.org/10.1007/s10815-017-1013-4
  70. Kaviani M, Ghaderian SMH, Arefi S, Hashemi M, Afjeh SSA. Role of FSHR rs6165 and ESR2 rs4986938 polymorphisms in ovarian stimulation of Iranian women who underwent assisted reproduction treatment. Hum Antibodies. 2017;26:3:121-126.  https://doi.org/10.3233/HAB-170329

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.